The North American market, containing many of the key players involved in global efforts to develop novel biotherapeutics, had a particularly strong start with a revenue growth of 100% compared to the same period in 2010. The number of service providers, such as CRO’s, implementing Gyrolab workstations into their projects also increased.
Commenting on the announcement, Erik Walldén, President and Chief Executive Officer of Gyros AB, said: “This positive trend confirms that our immunoassay platform is increasingly regarded as an established standard for many time-critical workflows in biotherapeutic development processes. This recognition is also reflected by the interest shown in our annual Gyrolab seminars, held in the USA and Europe, which attract scientists from across the industry.” Mr. Walldén continued, “Our growing installed base means significant growth in orders for consumables, especially our unique Gyrolab CDs in which the immunoassay steps take place under control of the workstation. Moving forward, Gyros is in an excellent position to set the industry standard for transforming the performance of immunoassays wherever they are utilized within the biopharmaceutical industry.”
The Company’s open, automated platform supports time-critical workflows in the biopharmaceutical industry, boosting productivity and cutting time to result. Automatically running immunoassays at nanoliter scale not only ensures faster development times, but also saves labor, sample and reagents. Assays are readily transferred downstream into GxP environments and between different sites, greatly facilitating collaborations between biopharmaceutical companies and their service providers. Having established the platform in the USA and Europe, Gyros is now focused on building awareness in Asia Pacific, where the Company recently announced that it has appointed a network of distributors.